DXCM Stock Analysis: DexCom | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 33.868m USD | 12M Return: 10.5% | US2521311074 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 437M
EPS Trend: 90.1%
Qual. Beats: 2
Rev. Trend: 99.1%
Qual. Beats: 2
Warnings
No concerns identified
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
DexCom, Inc. is a U.S.-based medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems used to manage diabetes and metabolic health. Its product portfolio spans the Dexcom G6, G7, and G7 15 Day systems, the over-the-counter Stelo biosensor for adults with prediabetes and Type 2 diabetes, the Dexcom ONE+ system, and the Share remote monitoring and Follow applications. The company sells primarily through a direct sales force targeting endocrinologists, physicians, and diabetes educators, and is headquartered in San Diego, California, having been incorporated in 1999.
As a Health Care Equipment company, DexCom operates in a sector where reimbursement from insurers and government payers is a key driver of adoption, and where CGM technology has increasingly displaced traditional fingerstick blood glucose testing in diabetes care. The CGM business model typically combines an initial hardware component with a recurring revenue stream from disposable sensors that must be replaced on a regular basis.
- Stelo OTC biosensor adoption drives new market expansion
- Abbott FreeStyle Libre competition pressures CGM market share
- Gross margins compress on pricing pressure and product mix
| Net Income: 999.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.22 > 0.02 and ΔFCF/TA 13.97 > 1.0 |
| NWC/Revenue: 34.79% < 20% (prev 40.03%; Δ -5.24% < -1%) |
| CFO/TA 0.27 > 3% & CFO 1.75b > Net Income 999.7m |
| Net Debt (-393.0m) to EBITDA (1.56b): -0.25 < 3 |
| Current Ratio: 1.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (391.8m) vs 12m ago -4.02% < -2% |
| Gross Margin: 62.47% > 18% (prev 58.77%; Δ 3.71% > 0.5%) |
| Asset Turnover: 72.11% > 50% (prev 58.70%; Δ 13.41% > 0%) |
| Interest Coverage Ratio: 86.33 > 6 (EBIT TTM 1.29b / Interest Expense TTM 15.0m) |
| A: 0.27 (Total Current Assets 4.09b - Total Current Liabilities 2.36b) / Total Assets 6.46b |
| B: 0.45 (Retained Earnings 2.88b / Total Assets 6.46b) |
| C: 0.19 (EBIT TTM 1.29b / Avg Total Assets 6.89b) |
| D: 0.68 (Book Value of Equity 2.62b / Total Liabilities 3.83b) |
| Altman-Z'' = 5.19 = AAA |
| DSRI: 0.81 (Receivables 1.28b/1.38b, Revenue 4.97b/4.30b) |
| GMI: 0.94 (GM 58.77% / 62.47%) |
| AQI: 1.02 (AQ_t 0.11 / AQ_t-1 0.11) |
| SGI: 1.16 (Revenue 4.97b / 4.30b) |
| TATA: -0.12 (NI 999.7m - CFO 1.75b) / TA 6.46b) |
| Beneish M = -3.13 (Cap -4..+1) = AA |
As of August 21, 2026, the stock is trading at USD 90.22 with a total of 5,164,526 shares traded. Over the past week, the price has changed by -1.38%, over one month by +19.20%, over three months by +26.29% and over the past year by +10.47%.
Current recommended Stop Loss: 86.90 (which is 3.7% or 1.2 ATR below the current price).
DexCom has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy DXCM.
- StrongBuy: 21
- Buy: 3
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 94.1 | 4.3% |
P/E Trailing = 35.4743
P/E Forward = 35.461
P/S = 6.8156
P/B = 12.9199
P/EG = 1.6933
Revenue TTM = 4.97b USD
EBIT TTM = 1.29b USD
EBITDA TTM = 1.56b USD
Long Term Debt = 1.24b USD (from longTermDebt, last quarter)
Short Term Debt = 20.7m USD (from shortTermDebt, last quarter)
Debt = 1.55b USD (from shortLongTermDebtTotal, last quarter) + Leases 155.6m
Net Debt = -393.0m USD (calculated: Debt 1.55b - CCE 1.95b)
Enterprise Value = 33.5b USD (33.9b + Debt 1.55b - CCE 1.95b)
Interest Coverage Ratio = 86.33 (Ebit TTM 1.29b / Interest Expense TTM 15.0m)
EV/FCF = 23.83x (Enterprise Value 33.5b / FCF TTM 1.41b)
FCF Yield = 4.20% (FCF TTM 1.41b / Enterprise Value 33.5b)
FCF Margin = 28.27% (FCF TTM 1.41b / Revenue TTM 4.97b)
Net Margin = 20.12% (Net Income TTM 999.7m / Revenue TTM 4.97b)
Gross Margin = 62.47% ((Revenue TTM 4.97b - Cost of Revenue TTM 1.86b) / Revenue TTM)
Gross Margin QoQ = 63.44% (prev 62.95%)
Tobins Q-Ratio = 5.19 (Enterprise Value 33.5b / Total Assets 6.46b)
Interest Expense / Debt = 0.97% (Interest Expense 15.0m / Debt 1.55b)
Taxrate = 21.90% (280.3m / 1.28b)
NOPAT = 1.01b (EBIT 1.29b * (1 - 21.90%))
Current Ratio = 1.73 (Total Current Assets 4.09b / Total Current Liabilities 2.36b)
Debt / Equity = 0.59 (Debt 1.55b / totalStockholderEquity, last quarter 2.62b)
Debt / EBITDA = -0.25 (Net Debt -393.0m / EBITDA 1.56b)
Debt / FCF = -0.28 (Net Debt -393.0m / FCF TTM 1.41b)
Total Stockholder Equity = 2.76b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.51% (Net Income 999.7m / Total Assets 6.46b)
RoE = 36.19% (Net Income TTM 999.7m / Total Stockholder Equity 2.76b)
RoCE = 32.33% (EBIT 1.29b / Capital Employed (Equity 2.76b + L.T.Debt 1.24b))
RoIC = 26.14% (NOPAT 1.01b / Invested Capital 3.87b)
WACC = 8.73% (E(33.9b)/V(35.4b) * Re(9.10%) + D(1.55b)/V(35.4b) * Rd(0.97%) * (1-Tc(0.22)))
Discount Rate = 9.10% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -94.07 | Cagr: -2.70%
[DCF] Terminal Value 76.74% ; FCFF base≈1.07b ; Y1≈1.23b ; Y5≈1.81b
[DCF] Fair Price = 68.56 (EV 25.5b - Net Debt -393.0m = Equity 25.9b / Shares 377.4m; r=8.73% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 90.13 | EPS CAGR: 19.63% | SUE: 2.19 | # QB: 2
Revenue Correlation: 99.14 | Revenue CAGR: 13.62% | SUE: 0.88 | # QB: 2
EPS current Quarter (2026-09-30): EPS=0.67 | Chg30d=-0.33% | Revisions=-11% | Analysts=21
EPS current Year (2026-12-31): EPS=2.66 | Chg30d=+2.85% | Revisions=+88% | GrowthEPS=+27.4% | GrowthRev=+12.2%
EPS next Year (2027-12-31): EPS=3.12 | Chg30d=+1.44% | Revisions=+56% | GrowthEPS=+17.4% | GrowthRev=+10.9%
[Analyst] Revisions Ratio: +55% (up=48, down=13)